Herpes zoster
☆ AI Dermatology — Free Service
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
Herpes zoster: Blasen am Hals an an de Schëller
relevance score : -100.0%
ReferencesShingles, verursaacht duerch d'Reaktivéierung vum Varicella Zoster Virus, verantwortlech fir Pouletpox, beaflosst all Joer ongeféier 1 Millioun Leit an den USA, mat engem Liewensrisiko vun 30 %. D'Leit mat geschwächtem Immunsystem sinn wesentlech méi ufälleg fir Shingles z'entwéckelen, mat Symptomer, déi typesch mat Malaise, Kappwéi an engem mëllen Féiwer ufänken, gefollegt vun ongewéinlechen Hautsensatiounen e puer Deeg virun der Erscheinung vun engem Ausschlag. Dësen Ausschlag, deen normalerweis an engem spezifesche Gebitt vum Kierper erschéngt, geet vu kloeren Bläsch bis zu zerstéierten Wunden iwwer eng Woch bis zéng Deeg. Eng prompt Behandlung mat antiviralen Medikamenter (acyclovir, valacyclovir, famciclovir) bannent 72 Stonnen nom Ausschlag ass entscheedend. Postherpetesch Neuralgie, eng heefeg Komplikatioun, déi duerch laangzäit Schmerzen am betraffenen Gebitt charakteriséiert ass, beaflosst ongeféier ee vu fënnef Patienten a erfuerdert eng laangfristeg Gestioun mat Medikamenter wéi Gabapentin, Pregabalin oder bestëmmte Antidepressiva, zesumme mat topeschen Agenzien wéi Lidokain oder Capsaicin. D'Impfung géint de Varicella Zoster Virus ass fir Erwuessener vu 50 Joren a méi recommandéiert, fir de Risiko vu Shingles ze reduzéieren.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster tritt méi dacks bei Leit vu 50 Joer a méi op, déi e schwächtes Immunsystem hunn, an déi Immunosuppressant‑Medikamenter huelen. Et gëtt ausgeléist duerch d'Reaktivéierung vum Varicella‑Zoster Virus, deem selwechte Virus, deen Waasserpoppen verursaacht. Symptomer wéi Féiwer, Péng an Jucken precedeieren d'Entstoeung vum charakteristesche Ausschlag. Déi heefegst Komplikatioun ass postherpetesch Neuralgie, wat persistente Nervenpains ass nodeems de Ausschlag opgeléist ass. D'Risikofaktoren a Komplikatioune, déi mat Herpes Zoster verbonnen sinn, variéieren no Alter, Immun‑Gesondheet an dem Timing vun der Behandlungsinitiatioun. D'Impfung fir Individuen vu 60 Joer a méi huet gewisen, datt d'Optriede vun Herpes Zoster an postherpetescher Neuralgie wesentlech reduzéiert gëtt. Antivirale Medikamenter an Analgetika bannent 72 Stonnen nom Ausschlag kënnen d'Gravitéit a Komplikatioune vu Herpes Zoster an postherpetescher Neuralgie reduzéieren.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Déi kleng Studien virun der Genehmigung weisen, datt d'Live‑Zoster‑Impfung ongeféier 50–70 % funktionnéiert, wärend d'Rekombinant‑Impfung besser funktionnéiert, mat enger Wirksamkeet vu 90–97 %. An Real‑Welt‑Studien ënnerstëtzen dës Resultater an weisen, datt d'Live‑Impfung ongeféier 46 % effektiv ass, wärend d'Rekombinant‑Impfung ongeféier 85 % ass.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
Waasserpocken, och Varicella genannt, entstinn aus der initialer Infektioun mam Virus, typesch während der Kandheet oder Jugend. Wann d'Waasserpocken geheelt sinn, kann de Virus fir Joer oder Joerzéngte an de mënschlechen Nervenzellen dormant bleiwen an duerno reaktivéiert ginn. Herpes zoster entsteht, wann de dormante Varicella‑Virus reaktivéiert gëtt. Da reest de Virus laanscht d'Nervekierper bis op d'Nerve‑Enden an der Haut a produzéiert Blasen. Wärend engem Ausbroch vu herpes zoster kann d'Belaaschtung vum Varicella‑Virus, deen d'Bléiser bei herpes zoster verursaacht, Waasserpocken verursaachen bei engem, deen nach keng Waasserpocken hat.
Risikofaktoren fir d'Reaktivéierung vum dormante Virus enthalen Alter, schwache Immunfunktioun an d'Fakt, datt een vir 18 Méint al Waasserpoken hat. Varicella Zoster Virus ass net dat selwecht wéi Herpes Simplex Virus, obwuel béid zur selwechter Famill vun Herpesvirussen gehéieren.
Herpes zoster‑Impfungen reduzéieren de Risiko vun herpes zoster ëm 50 % bis 90 %. Si reduzéieren och d'Incidenz vun der postherpetescher Neuralgie an d'Gravitéit, wann se optrëtt. Wann herpes zoster entwéckelt, kënnen antiviral Medikamenter wéi Aciclovir d'Gravitéit an d'Dauer vun der Krankheet reduzéieren, wann se bannent 72 Stonnen no der Erscheinung vum Ausschlag gestart ginn.
○ Behandlung
Wann d'Läsionen séier fortschrëtt, sollt Dir sou séier wéi méiglech Ären Dokter fir eng antiviral Behandlung kontaktéieren.
Sowohl antiviral Medikamenter wéi och Medikamenter géint Neuralgie sinn néideg. Dir sollt Alkohol vermeiden.
#Acyclovir
#Famciclovir
#Valacyclovir
#Gabapentin
#Pregabalin